Health Technology

AnGes, Inc.

In the news

AstraZeneca to supply Japan with 120m COVID-19 vaccine doses Aug 8, 2020
AstraZeneca virus vaccine shows promise in trial Jul 21, 2020
Japan to pool $20bn with Europe, Canada for vaccine-buying fund Jul 8, 2020
Japan in talks to secure coronavirus vaccine from AstraZeneca Jun 27, 2020
Japan to ready 1m doses of coronavirus vaccine for swift distribution Jun 20, 2020

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2021	JPY	USD
Revenue	64.14M	0.58M
Gross Profit	-2,410.09M	-21.93M
Operating income	-15,632.08M	-142.27M
Income before tax	-13,735.29M	-125.01M
Net income	-13,675.58M	-124.46M
EBITDA	-13,206.00M	-120.19M
Diluted EPS	-92.85	-0.84
Dividends Per Share	0	0
Total Assets	45,455.74M	394.73M
Total liabilities	6,821.00M	59.23M
Total equity	38,634.74M	335.50M
Operating cash flow	-11,380.54M	-103.57M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	365.18M	610.05M	326.75M	39.99M	64.14M
Gross Profit	163.69M	418.87M	235.16M	12.06M	-2,410.09M
Operating income	-3,288.68M	-3,065.25M	-3,270.00M	-5,599.39M	-15,632.08M
Income before tax	-3,744.18M	-3,003.00M	-3,751.60M	-4,204.95M	-13,735.29M
Net income	-3,764.69M	-2,996.62M	-3,750.82M	-4,209.51M	-13,675.58M
EBITDA	-3,259.32M	-3,057.39M	-3,262.68M	-5,591.80M	-13,206.00M
Diluted EPS	-49.38	-34.46	-35.81	-35.32	-92.85
Dividends Per Share	0	0	0	0	0
Total Assets	3,963.60M	8,050.67M	12,524.60M	38,354.61M	45,455.74M
Total liabilities	341.72M	316.21M	469.24M	5,674.93M	6,821.00M
Total equity	3,621.88M	7,734.45M	12,055.35M	32,679.67M	38,634.74M
Operating cash flow	-2,991.22M	-2,522.50M	-2,179.91M	-2,961.32M	-11,380.54M

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	3.25M	5.52M	2.99M	0.37M	0.58M
Gross Profit	1.45M	3.79M	2.15M	0.11M	-21.93M
Operating income	-29.32M	-27.75M	-29.99M	-52.44M	-142.27M
Income before tax	-33.39M	-27.19M	-34.41M	-39.38M	-125.01M
Net income	-33.57M	-27.13M	-34.40M	-39.42M	-124.46M
EBITDA	-29.06M	-27.68M	-29.92M	-52.37M	-120.19M
Diluted EPS	-0.44	-0.31	-0.32	-0.33	-0.84
Dividends Per Share	0	0	0	0	0
Total Assets	35.18M	73.37M	115.24M	371.49M	394.73M
Total liabilities	3.03M	2.88M	4.31M	54.96M	59.23M
Total equity	32.15M	70.49M	110.93M	316.52M	335.50M
Operating cash flow	-26.67M	-22.83M	-19.99M	-27.73M	-103.57M

Valuation Measures

Dec 2021
PER	--
ROA	-32.63%
ROE	-38.35%
Operating margin	-24,368.77%
Profit margin	-21,318.80%

Key executives

President & Representative Director: Ei Yamada
Director, Executive Officer & Manager-Finance: Tetsuji Yoneo
Director & Manager-Drug Discovery Research: Kazuo Suzuki
Executive Officer, Manager-R&D Promotion: Hajime Watanabe
Manager-Accounting: Jun Sakurai

Shareholders

OrbiMed Advisors Private Equity (3.8%)
BlackRock Fund Advisors (1.3%)
Shionogi & Co., Ltd. (0.7%)
MORISHITA RYUICHI (0.4%)
BlackRock Advisors (UK) Ltd. (0.2%)
TIAA-CREF Investment Management LLC (0.1%)
SSgA Funds Management, Inc. (0.0%)
Geode Capital Management LLC (0.0%)
Credit Suisse Asset Management (Schweiz) AG (0.0%)
ISHIHARA SANGYO KAISHA LTD. (0.0%)

Contact Details

Website:http://www.anges.co.jp
Address: Saito Bio-Incubator, 1/F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
Phone: +81.72.643.3590

Related Companies

Emendo Biotherapeutics, Inc.
AnGes USA, Inc.
AnGes Euro Ltd.

Competitors

Sienna Biopharmaceuticals, Inc.
Athira Pharma, Inc.

Last Updated on 24 May, 2022